Will Chemours disclose DuPont MOU remaining capacity below $500M (its $2B share) by 2026-12-31?
Current Prediction
Why This Question Matters
The single most important factual correction in Black Swan Beacon: the DuPont MOU $4B aggregate ($2B Chemours share) caps cost-sharing, not total liability. Post-exhaustion Chemours bears 100% of incremental PFAS costs. This market tests the leading indicator — whether 2026 settlement drawdown crosses the $500M-remaining threshold, signaling near-term exposure to 100% liability basis. Bridges FUNDING_FRAGILITY and ASSUMPTION_FRAGILITY.
Prediction Distribution
Individual Predictions(9 runs)
Starting balance ~$1.xB (call it $1.2B midpoint). To cross below $500M requires $700M of drawdown in 8 months (April to December 2026). Historical annual drawdown pace is $100-400M. At high end of historical pace ($400M annualized → $267M in 8 months), not enough. Crossing requires either acceleration (multiple large state settlements) or a single global MDL settlement event. Probability of acceleration: ~30-40% given multiple state actions in pipeline. Probability of global MDL settlement: ~20%. OR combined: ~0.45. But conditional on acceleration/global settlement occurring, probability of crossing threshold is ~60% (depends on settlement size). Joint: ~0.27. Settle 0.28.
Upward adjustment given: (a) NC bellwether trial pressure could catalyze global MDL settlement push in H2 2026 (correlation with other markets), (b) RICO survival (if motion denied) would accelerate settlement cadence, (c) state actions (OH, MI, MN, WA in pipeline) could stack. The compound correlation is real — if PFAS tide turns generally, all three (NC verdict + RICO survival + MOU drawdown) accelerate together. Black Swan Beacon explicit about this correlation. 0.32 captures upside adjustment.
Disclosure granularity risk pulls down: Chemours has incentive to preserve MOU negotiating position and may shift to qualitative disclosure as balance approaches $500M threshold. Under strict criteria, a shift to qualitative disclosure resolves NO. Additionally, defense-side procedural delays can slow settlement pace — NC trial outcome, RICO motion, and state attorney-general strategy all shape cadence. Net 0.25 reflects disclosure risk + procedural delay scenarios.
Math: $1.2B midpoint start, need $700M drawdown in 8 months. Annualized pace would need to be $1.05B/year, vs historical $100-400M. Required acceleration 2.5-10x. Catalysts that could produce such acceleration: multi-state settlement coordination, global MDL settlement, large single settlement (NJ-scale x 3). Probability of at least one such catalyst by year-end 2026: ~30-40%. Conditional probability of sufficient magnitude: ~70%. Joint 0.28.
Conservative view: most settlement cadence risk already priced into 2026 expectations. Chemours' explicit disclosure of remaining capacity is a recurring 10-Q item but may shift to range-based if approaching threshold. Litigation 2026 likely sees NC trial focus, RICO motion, then settlement discussions in late 2026 if adverse outcomes. Resolution date Dec 31 captures some but not all of this. 0.25.
Balanced view: correlation with other PFAS markets argues for elevated joint probability, but required drawdown magnitude is high. Black Swan Beacon flagged this threshold as monitoring trigger — committee believes probability meaningful but not high. 0.30.
Starting $1.2B midpoint, needs $700M drawdown = 2.5-10x historical. Probability ~25%. Slight upward for correlation with NC/RICO. Net 0.26.
30% captures balanced view of catalyst-driven acceleration versus disclosure-granularity risk. Middle of opus range.
Settlement cadence + correlation with other PFAS catalysts + disclosure risk balance near 28%. Settle 0.28.
Resolution Criteria
Resolves YES if any Chemours filing (10-Q, 10-K, 8-K) or earnings commentary through 2026-12-31 explicitly discloses remaining DuPont MOU capacity (Chemours $2B share basis) below $500M, OR discloses MOU exhaustion, OR discloses any state/water utility settlement that mathematically reduces remaining capacity below $500M when combined with previously-disclosed drawdown. Resolves NO if (a) disclosed remaining capacity remains at or above $500M through 2026-12-31, (b) Chemours ceases specific disclosure of remaining capacity, or (c) the MOU structure is amended/renegotiated in a way that changes the cap structure.
Resolution Source
Chemours 10-Q, 10-K, 8-K filings, earnings conference call disclosures
Source Trigger
DuPont MOU Remaining Capacity — Disclosed remaining capacity below $500M or any exhaustion event
Full multi-lens equity analysis